Merck Sharp & Dohme Corp. 4
4 · NGM BIOPHARMACEUTICALS INC · Filed Apr 9, 2019
Insider Transaction Report
Form 4
Merck & Co., Inc.
10% Owner
Transactions
- Conversion
Common Stock
2019-04-08+8,833,333→ 8,833,333 total(indirect: See Footnote) - Purchase
Common Stock
2019-04-08$16.00/sh+4,121,683$65,946,928→ 12,955,016 total(indirect: See Footnote) - Conversion
Series E Convertible Preferred Stock
2019-04-08−17,666,666→ 0 total(indirect: See Footnote)→ Common Stock (8,333,333 underlying)
Footnotes (2)
- [F1]Each share of Series E Convertible Preferred Stock automatically converted into one-half (0.5) of a share of common stock immediately prior to the closing of the Issuer's initial public offering, and has no expiration date.
- [F2]These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. ("Merck"). Merck is an indirect beneficial owner of the reported securities.